COSMO PHARMACEUTICALS NV (C43.DE) Stock Fundamental Analysis
Europe - FRA:C43 - NL0011832936 - Common Stock
48.8 EUR
-1.2 (-2.4%)
Overall C43 gets a fundamental rating of 8 out of 10. We evaluated C43 against 54 industry peers in the Pharmaceuticals industry. C43 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. An interesting combination arises when we look at growth and value: C43 is growing strongly while it also seems undervalued. C43 also has an excellent dividend rating. With these ratings, C43 could be worth investigating further for value and dividend and growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year C43 was profitable.
C43 had a positive operating cash flow in the past year.
In multiple years C43 reported negative net income over the last 5 years.
In the past 5 years C43 always reported a positive cash flow from operatings.
1.2 Ratios
C43 has a better Return On Assets (20.60%) than 94.23% of its industry peers.
C43 has a better Return On Equity (26.74%) than 76.92% of its industry peers.
C43's Return On Invested Capital of 21.60% is amongst the best of the industry. C43 outperforms 88.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROIC | 21.6% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 49.94%, C43 belongs to the top of the industry, outperforming 98.08% of the companies in the same industry.
In the last couple of years the Profit Margin of C43 has grown nicely.
C43's Operating Margin of 55.81% is amongst the best of the industry. C43 outperforms 100.00% of its industry peers.
In the last couple of years the Operating Margin of C43 has grown nicely.
C43 has a better Gross Margin (83.00%) than 86.54% of its industry peers.
In the last couple of years the Gross Margin of C43 has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% |
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), C43 is creating value.
C43 has less shares outstanding than it did 1 year ago.
The number of shares outstanding for C43 has been increased compared to 5 years ago.
C43 has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.80 indicates that C43 is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.80, C43 belongs to the top of the industry, outperforming 90.38% of the companies in the same industry.
C43 has a debt to FCF ratio of 0.01. This is a very positive value and a sign of high solvency as it would only need 0.01 years to pay back of all of its debts.
The Debt to FCF ratio of C43 (0.01) is better than 98.08% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that C43 is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, C43 belongs to the top of the industry, outperforming 94.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Altman-Z | 5.8 |
ROIC/WACC2.81
WACC7.68%
2.3 Liquidity
C43 has a Current Ratio of 4.19. This indicates that C43 is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of C43 (4.19) is better than 96.15% of its industry peers.
C43 has a Quick Ratio of 3.91. This indicates that C43 is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 3.91, C43 belongs to the best of the industry, outperforming 96.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 1315.29% over the past year.
Measured over the past years, C43 shows a very strong growth in Earnings Per Share. The EPS has been growing by 85.20% on average per year.
The Revenue has grown by 187.55% in the past year. This is a very strong growth!
The Revenue has been growing by 33.68% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
3.2 Future
The Earnings Per Share is expected to grow by 29.02% on average over the next years. This is a very strong growth
C43 is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.67% yearly.
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 5.98, which indicates a rather cheap valuation of C43.
92.31% of the companies in the same industry are more expensive than C43, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 25.89. C43 is valued rather cheaply when compared to this.
C43 is valuated reasonably with a Price/Forward Earnings ratio of 8.09.
Based on the Price/Forward Earnings ratio, C43 is valued cheaply inside the industry as 84.62% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.59, C43 is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of C43 indicates a rather cheap valuation: C43 is cheaper than 96.15% of the companies listed in the same industry.
C43's Price/Free Cash Flow ratio is rather cheap when compared to the industry. C43 is cheaper than 94.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.46 | ||
| EV/EBITDA | 3.83 |
4.3 Compensation for Growth
The excellent profitability rating of C43 may justify a higher PE ratio.
A cheap valuation may be justified as C43's earnings are expected to decrease with -27.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
5. Dividend
5.1 Amount
C43 has a Yearly Dividend Yield of 3.85%. Purely for dividend investing, there may be better candidates out there.
In the last 3 months the price of C43 has falen by -28.24%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 2.88, C43 pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.42, C43 pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
5.2 History
On average, the dividend of C43 grows each year by 7.41%, which is quite nice.
Dividend Growth(5Y)7.41%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
C43 pays out 24.09% of its income as dividend. This is a sustainable payout ratio.
The dividend of C43 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP24.09%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
FRA:C43 (4/29/2025, 7:00:00 PM)
48.8
-1.2 (-2.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.98%
Inst Owner ChangeN/A
Ins Owners38.78%
Ins Owner ChangeN/A
Market Cap855.95M
Revenue(TTM)266.79M
Net Income(TTM)133.24M
Analysts84
Price Target104.72 (114.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
Yearly Dividend2
Dividend Growth(5Y)7.41%
DP24.09%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.87%
Revenue NY rev (3m)-12.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 | ||
| P/S | 3.21 | ||
| P/FCF | 5.46 | ||
| P/OCF | 5.27 | ||
| P/B | 1.72 | ||
| P/tB | 6.01 | ||
| EV/EBITDA | 3.83 |
EPS(TTM)8.16
EY16.72%
EPS(NY)6.03
Fwd EY12.36%
FCF(TTM)8.94
FCFY18.31%
OCF(TTM)9.26
OCFY18.97%
SpS15.21
BVpS28.41
TBVpS8.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROCE | 24.88% | ||
| ROIC | 21.6% | ||
| ROICexc | 28.38% | ||
| ROICexgc | 129.8% | ||
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% | ||
| FCFM | 58.76% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y181.33%
ROICexgc growth 5YN/A
ROICexc growth 3Y154.84%
ROICexc growth 5YN/A
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 46.02% | ||
| Cap/Sales | 2.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 100.77% | ||
| Profit Quality | 117.65% | ||
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z | 5.8 |
F-Score8
WACC7.68%
ROIC/WACC2.81
Cap/Depr(3y)45.29%
Cap/Depr(5y)77.05%
Cap/Sales(3y)4.67%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
EBIT growth 1Y8040.37%
EBIT growth 3Y137.59%
EBIT growth 5YN/A
EBIT Next Year-33.52%
EBIT Next 3Y-14.79%
EBIT Next 5Y28.59%
FCF growth 1Y756.04%
FCF growth 3Y236.69%
FCF growth 5YN/A
OCF growth 1Y615.22%
OCF growth 3Y134.4%
OCF growth 5YN/A
COSMO PHARMACEUTICALS NV / C43.DE FAQ
What is the ChartMill fundamental rating of COSMO PHARMACEUTICALS NV (C43.DE) stock?
ChartMill assigns a fundamental rating of 9 / 10 to C43.DE.
What is the valuation status of COSMO PHARMACEUTICALS NV (C43.DE) stock?
ChartMill assigns a valuation rating of 8 / 10 to COSMO PHARMACEUTICALS NV (C43.DE). This can be considered as Undervalued.
How profitable is COSMO PHARMACEUTICALS NV (C43.DE) stock?
COSMO PHARMACEUTICALS NV (C43.DE) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for C43 stock?
The Price/Earnings (PE) ratio for COSMO PHARMACEUTICALS NV (C43.DE) is 5.98 and the Price/Book (PB) ratio is 1.72.
Can you provide the financial health for C43 stock?
The financial health rating of COSMO PHARMACEUTICALS NV (C43.DE) is 9 / 10.